Academic medical center
Appears in 5 stories · Last updated Oct 26, 2026
Lead trial site for AMPLIFY-7P
About 90% of pancreatic cancers are driven by mutations in the KRAS gene, long considered undruggable. The experimental vaccine camupepimut (ELI-002 7P) targets seven common KRAS mutations, and 89 of 90 evaluable patients (98.9%) developed KRAS-specific T-cell responses in the phase 2 AMPLIFY-7P trial.
Updated Oct 26
As of October 2026: Originator of the D+Q senolytic approach
Eight of 17 patients whose fatty liver disease had progressed to scarring saw their fibrosis improve after 21 weeks of intermittent treatment with two drugs. One of 14 on placebo did. The randomized, placebo-controlled result, published in Nature Metabolism, is the first controlled evidence that clearing senescent cells can reverse liver fibrosis in people.
Updated Oct 7
As of September 2026: Conducted the N-of-1 clinical study
A physician with a rare inherited form of amyotrophic lateral sclerosis (ALS) received a drug built around his own gene mutation, the first therapy designed for this genetic form of the disease. A year after his first dose, his neuron-damage biomarker fell into the normal range and he kept practicing medicine.
Updated Sep 21
As of June 2026: Anchor sequencing partner for Helix
Helix said its GenoSphere platform now holds more than 500,000 linked clinico-genomic records. That makes it the largest such dataset in North America. The San Mateo company also released the first of a planned set of artificial intelligence tools built to mine that data for drug targets.
Updated Jun 2
As of May 2026: Developer of REDMOD; running the AI-PACED clinical trial
Pancreatic cancer kills nearly nine in ten patients within five years, mostly because doctors catch it too late to operate. On April 28, 2026, Mayo Clinic researchers published a validation study showing their artificial intelligence model can flag the disease on routine CT scans up to three years before a clinical diagnosis.
Updated May 31
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
